[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
quantumup @Quantumup1 on x 3524 followers
Created: 2025-07-15 12:59:17 UTC
BofA reit'd $PRCT Buy-$84 after Center of Medicare and Medicaid Services (CMS) released its proposed physician fee schedule (PFS) for 2026 which includes what a doctor will get paid to perform PRCT's Aquablation under its new Category I CPT code. $BSX $ISRG $SYK $MDT $GEHC BofA said, "In the release, physician fees for most resective #BPH procedures fell more than XX% on average (Aquablation down ~28%) which we believe was expected. Importantly, we do not expect the doc payment cuts to have much impact on PRCT's momentum because
- Aquablation adoption thus far has been based on impressive clinical results and the ability to standardize across a wide range of prostate sizes in our view and
- urologists will continue to get paid roughly the same for Aquablation or a resective #BPH procedure (TURP, Greenlight).
Investors were concerned that adoption may slow if Aquablation surgeon payment fell below alternative procedures. We expect those specific concerns to ease following the PFS release and believe any overhang on the stock should subside quickly.
We maintain our Buy rating as we believe $PRCT has one of the most compelling growth stories in medtech and could become the standard of care for #BPH."
XXXXX engagements
Related Topics $gehc $prct $bsx boston scientific stocks healthcare $isrg $syk $mdt